Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Anterior gradient 3 (AGR3) belongs to human anterior gradient (AGR) family. The function of AGR3 on cancer remains unknown. This research aimed to investigate if AGR3 had prognostic values in invasive ductal carcinoma (IDC) of breast cancer and could promote tumor progression. Materials and Methods AGR3 expression was detected in breast benign lesions, ductal carcinoma in situ and IDC by immunohistochemistry analysis. AGR3’s correlations with clinicopathological features and prognosis of IDC patients were analyzed. By cell function experiments, collagen gel droplet-embedded culture drug sensitivity test and cytotoxic analysis, AGR3’s impacts on proliferation, invasion ability, and chemotherapeutic drug sensitivity of breast cancer cells were also detected. Results AGR3 was up-regulated in luminal subtype of histological grade I-II of IDC patients and positively correlated with high risks of recurrence and distant metastasis. AGR3 high expression could lead to bone or liver metastasis and predict poor prognosis of luminal B. In cell lines, AGR3 could promote proliferation and invasion ability of breast cancer cells which were consistent with clinical analysis. Besides, AGR3 could indicate poor prognosis of breast cancer patients treated with taxane but a favorable prognosis with 5-fluoropyrimidines. And breast cancer cells with AGR3 high expression were resistant to taxane but sensitive to 5-fluoropyrimidines. Conclusion AGR3 might be a potential prognostic indicator in luminal B subtype of IDC patients of histological grade I-II. And patients with AGR3 high expression should be treated with chemotherapy regimens consisting of 5-fluoropyrimidines but no taxane.
Abstract
Purpose Anterior gradient 3 (AGR3) belongs to human anterior gradient (AGR) family. The function of AGR3 on cancer remains unknown. This research aimed to investigate if AGR3 had prognostic values in invasive ductal carcinoma (IDC) of breast cancer and could promote tumor progression. Materials and Methods AGR3 expression was detected in breast benign lesions, ductal carcinoma in situ and IDC by immunohistochemistry analysis. AGR3’s correlations with clinicopathological features and prognosis of IDC patients were analyzed. By cell function experiments, collagen gel droplet-embedded culture drug sensitivity test and cytotoxic analysis, AGR3’s impacts on proliferation, invasion ability, and chemotherapeutic drug sensitivity of breast cancer cells were also detected. Results AGR3 was up-regulated in luminal subtype of histological grade I-II of IDC patients and positively correlated with high risks of recurrence and distant metastasis. AGR3 high expression could lead to bone or liver metastasis and predict poor prognosis of luminal B. In cell lines, AGR3 could promote proliferation and invasion ability of breast cancer cells which were consistent with clinical analysis. Besides, AGR3 could indicate poor prognosis of breast cancer patients treated with taxane but a favorable prognosis with 5-fluoropyrimidines. And breast cancer cells with AGR3 high expression were resistant to taxane but sensitive to 5-fluoropyrimidines. Conclusion AGR3 might be a potential prognostic indicator in luminal B subtype of IDC patients of histological grade I-II. And patients with AGR3 high expression should be treated with chemotherapy regimens consisting of 5-fluoropyrimidines but no taxane.
참고문헌 (30)
- Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
- Mendes TF, "Triple negative breast cancer : nanosolutions for a big challenge", Adv Sci(Weinh), 2, pp.1500053~ (2015)
- Abdel-Hafiz HA, "Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer", Diseases, 5, pp.E16~ (2017)
- Hart CD, "Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes", Breast, 2, pp.S136~42 (2015)
- Tran B, "Luminal-B breast cancer and novel therapeutic targets", Breast Cancer Res, 13, pp.221~ (2011)
- Ivanova AS, "Agr genes, missing in amniotes, are involved in the body appendages regeneration in frog tadpoles", Sci Rep, 3, pp.1279~ (2013)
- Thompson DA, "hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines", Biochem Biophys Res Commun, 251, pp.111~116 (1998)
- Fletcher GC, "hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan", Br J Cancer, 88, pp.579~585 (2003)
- Wilson CL, "Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue", Endocr Relat Cancer, 13, pp.617~628 (2006)
- Hrstka R, "The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers", Oncogene, 29, pp.4838~4847 (2010)
- 이제호, "AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration", Experimental and Molecular Medicine, 43(2), pp.91~100 (2011), 생화학분자생물학회
- Zhang JS, "AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer", Genes Chromosomes Cancer, 43, pp.249~259 (2005)
- Pohler E, "The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage", Mol Cell Proteomics, 3, pp.534~547 (2004)
- Fritzsche FR, "Expression of AGR2 in non small cell lung cancer", Histol Histopathol, 22, pp.703~708 (2007)
- Ramachandran V, "Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival", Cancer Res, 68, pp.7811~7818 (2008)
- Adam PJ, "Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer", J Biol Chem, 278, pp.6482~6489 (2003)
- Garczyk S, "AGR3 in breast cancer : prognostic impact and suitable serum-based biomarker for early cancer detection", PLoS One, 10, pp.e0122106~ (2015)
- Li H, "15-Deoxy-!(12, 14)-prostaglandin J(2)induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer cell lines", Int J Mol Med, 31, pp.778~788 (2013)
- Pascal LE, "Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes", BMC Cancer, 9, pp.452~ (2009)
- Gray TA, "Anterior Gradient-3 : a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models", J Immunol Methods, 378, pp.20~32 (2012)
- Vaarala MH, "Identification of androgen-regulated genes in human prostate", Mol Med Rep, 6, pp.466~472 (2012)
- Bu H, "Anterior gradient 2 and 3 : two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells", FEBS J, 280, pp.1249~1266 (2013)
- Obacz J, "Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients", Onco Targets Ther, 8, pp.1523~1532 (2015)
- King ER, "The anterior gradient homolog 3(AGR3)gene is associated with differentiation and survival in ovarian cancer", Am J Surg Pathol, 35, pp.904~912 (2011)
- Welboren WJ, "ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands", EMBO J, 28, pp.1418~1428 (2009)
- Mhaidat NM, "Involvement of endoplasmic reticulum stress in Docetaxel-induced JNKdependent apoptosis of human melanoma", Apoptosis, 13, pp.1505~1512 (2008)
- McGrath EP, "The unfolded protein response in breast cancer", Cancers(Basel), 10, pp.E344~ (2018)
- Ryu J, "Dimerization of pro-oncogenic protein Anterior Gradient 2 is required for the interaction with BiP", GRP78, 2013, pp.430, 610~615
- Kim JK, "Endoplasmic reticulum stress induces 5-fluorouracil resistance in human colon cancer cells", Environ Toxicol Pharmacol, 44, pp.128~133 (2016)
- Yun S, "Enhanced susceptibility to 5-fluorouracil in human colon cancer cells by silencing of GRP78", Anticancer Res, 37, pp.2975~2984 (2017)